Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-5 (of 5 Records) |
Query Trace: Sulemana I[original query] |
---|
Continued evidence of the impact of rotavirus vaccine in children less than 3 years of age from the US New Vaccine Surveillance Network- a multi-site active surveillance program, 2006-2016
Staat MA , Payne DC , Halasa N , Weinberg GA , Donauer S , Wikswo M , McNeal M , Edwards KM , Szilagyi PG , Bernstein DI , Curns AT , Sulemana I , Esona MD , Bowen MD , Parashar UD . Clin Infect Dis 2020 71 (9) e421-e429 BACKGROUND: Since 2006, the New Vaccine Surveillance Network has conducted active, population-based surveillance for acute gastroenteritis (AGE) hospitalizations and emergency department (ED) visits in three US counties. Trends in the epidemiology and disease burden of rotavirus hospitalizations and ED visits were examined from 2006-2016. METHODS: Children <3 years of age hospitalized or visiting the ED with AGE, were enrolled from January 2006-June 2016. Bulk stool specimens were collected and tested for rotavirus. Rotavirus-associated hospitalization and ED visit rates were calculated annually with 2006-2007 defined as pre-vaccine and 2008-2016 as post-vaccine periods. Rotavirus genotype trends were compared over time. RESULTS: Over 11 seasons, 6954 children with AGE were enrolled and submitted a stool specimen (2187 hospitalized and 4767 in the ED). Comparing pre- and post-vaccine periods, the proportion of children with rotavirus dramatically declined for hospitalization (49% vs 10%) and ED visits (49% vs 8%). In the post-vaccine era, a biennial pattern of rotavirus rates was observed, with a trend toward an older median age. G1P[8] (63%) was the predominant genotype in the pre-vaccine period with a significantly lower proportion (7%) in the post-vaccine period (p<.001). G2P[4] remained stable (8% to 14%) in both periods, while G3P[8] and G12P[8] increased in proportion from pre-to post-vaccine periods (1% to 25% and 17% to 40%) respectively. CONCLUSIONS: The epidemiology and disease burden of rotavirus has been altered by rotavirus vaccination with a biennial disease pattern, sustained low rates of rotavirus in children <3 years of age and a shift in the residual genotypes from G1P[8] to other genotypes. |
Association of rotavirus vaccination with inpatient and emergency department visits among children seeking care for acute gastroenteritis, 2010-2016
Payne DC , Englund JA , Weinberg GA , Halasa NB , Boom JA , Staat MA , Selvarangan R , Azimi PH , Klein EJ , Szilagyi PG , Chappell J , Sahni LC , McNeal M , Harrison CJ , Moffatt ME , Johnston SH , Mijatovic-Rustempasic S , Esona MD , Tate JE , Curns AT , Wikswo ME , Sulemana I , Bowen MD , Parashar UD . JAMA Netw Open 2019 2 (9) e1912242 Importance: Rotavirus vaccines have been recommended for universal US infant immunization for more than 10 years, and understanding their effectiveness is key to the continued success of the US rotavirus vaccine immunization program. Objective: To assess the association of RotaTeq (RV5) and Rotarix (RV1) with inpatient and emergency department (ED) visits for rotavirus infection. Design, Setting, and Participants: This case-control vaccine effectiveness study was performed at inpatient and ED clinical settings in 7 US pediatric medical institutions from November 1, 2009, through June 30, 2016. Children younger than 5 years seeking medical care for acute gastroenteritis were enrolled. Clinical and epidemiologic data, vaccination verification, and results of stool sample tests for laboratory-confirmed rotavirus were collected. Data were analyzed from November 1, 2009, through June 30, 2016. Main Outcomes and Measures: Rotavirus vaccine effectiveness for preventing rotavirus-associated inpatient and ED visits over time for each licensed vaccine, stratified by clinical severity and age. Results: Among the 10 813 children included (5927 boys [54.8%] and 4886 girls [45.2%]; median [range] age, 21 [8-59] months), RV5 and RV1 analyses found that compared with controls, rotavirus-positive cases were more often white (RV5, 535 [62.2%] vs 3310 [57.7%]; RV1, 163 [43.1%] vs 864 [35.1%]), privately insured (RV5, 620 [72.1%] vs 4388 [76.5%]; RV1, 305 [80.7%] vs 2140 [87.0%]), and older (median [range] age for RV5, 26 [8-59] months vs 21 [8-59] months; median [range] age for RV1, 22 [8-59] months vs 19 [8-59] months) but did not differ by sex. Among 1193 rotavirus-positive cases and 9620 rotavirus-negative controls, at least 1 dose of any rotavirus vaccine was 82% (95% CI, 77%-86%) protective against rotavirus-associated inpatient visits and 75% (95% CI, 71%-79%) protective against rotavirus-associated ED visits. No statistically significant difference during this 7-year period was observed for either rotavirus vaccine. Vaccine effectiveness against inpatient and ED visits was 81% (95% CI, 78%-84%) for RV5 (3 doses) and 78% (95% CI, 72%-82%) for RV1 (2 doses) among the study population. A mixed course of both vaccines provided 86% (95% CI, 74%-93%) protection. Rotavirus patients who were not vaccinated had severe infections 4 times more often than those who were vaccinated (74 of 426 [17.4%] vs 28 of 605 [4.6%]; P < .001), and any dose of rotavirus vaccine was 65% (95% CI, 56%-73%) effective against mild infections, 81% (95% CI, 76%-84%) against moderate infections, and 91% (95% CI, 85%-95%) against severe infections. Conclusions and Relevance: Evidence from this large postlicensure study of rotavirus vaccine performance in the United States from 2010 to 2016 suggests that RV5 and RV1 rotavirus vaccines continue to perform well, particularly in preventing inpatient visits and severe infections and among younger children. |
Evaluation of effectiveness of mixed rotavirus vaccine course for rotavirus gastroenteritis
Payne DC , Sulemana I , Parashar UD . JAMA Pediatr 2016 170 (7) 708-10 Two rotavirus vaccines—RotaTeq (RV5; Merck and Company), a 3-dose series, and Rotarix (RV1; GlaxoSmithKline Biologicals), a 2-dose series—are licensed for use in US children. The US Advisory Committee for Immunization Practices (ACIP) recommends that a rotavirus vaccine series be completed with the same product whenever possible but allows for administering mixed vaccine types if a previous dose type is not available or is unknown.1 In such situations, the ACIP recommends, “If any dose in the series was RV5 or the vaccine product is unknown for any dose in the series, a total of 3 doses of rotavirus vaccine should be administered.”1 However, the effectiveness of a mixed rotavirus vaccine series remains unclear. | We evaluated the postlicensure vaccine effectiveness (VE) of a complete 3-dose course of mixed rotavirus vaccine types according to the ACIP definition and compared these results with published VE results for the same population and time. |
Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012-2013
Payne DC , Selvarangan R , Azimi PH , Boom JA , Englund JA , Staat MA , Halasa NB , Weinberg GA , Szilagyi PG , Chappell J , McNeal M , Klein EJ , Sahni LC , Johnston SH , Harrison CJ , Baker CJ , Bernstein DI , Moffatt ME , Tate JE , Mijatovic-Rustempasic S , Esona MD , Wikswo ME , Curns AT , Sulemana I , Bowen MD , Gentsch JR , Parashar UD . Clin Infect Dis 2015 61 (12) 1792-9 BACKGROUND: Using a multi-center, active surveillance network from two rotavirus seasons (2012 and 2013), we assessed the vaccine effectiveness of RV5 (RotaTeq) and RV1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency department (ED) visits for numerous demographic and secular strata. METHODS: We enrolled children hospitalized or visiting the ED with acute gastroenteritis (AGE) for the 2012 and 2013 seasons at 7 medical institutions. Stool specimens were tested for rotavirus by enzyme immunoassay and genotyped, and rotavirus vaccination histories were compared for rotavirus-positive cases and rotavirus-negative AGE controls. We calculated the VE for preventing rotavirus associated hospitalizations and ED visits for each vaccine, stratified by vaccine dose, season, clinical setting, age, predominant genotype, and ethnicity. RESULTS: RV5-specific VE analyses included 2,961 subjects, 402 rotavirus cases (14%) and 2,559 rotavirus-negative AGE controls. RV1-specific VE analyses included 904 subjects, 100 rotavirus cases (11%) and 804 rotavirus-negative AGE controls. Over the two rotavirus seasons, the VE for a complete 3-dose vaccination with RV5 was 80% (CI= 74% - 84%), and VE for a complete 2-dose vaccination with RV1 was 80% (CI= 68% - 88%).Statistically significant VE was observed for each year of life for which sufficient data allowed analysis (7 years for RV5 and 3 years for RV1). Both vaccines provided statistically significant genotype-specific protection against predominant circulating rotavirus strains. CONCLUSION: In this large, geographically and demographically diverse sample of US children, we observed that RV5 and RV1 rotavirus vaccines each provided a lasting, and broadly heterologous protection against rotavirus gastroenteritis. |
Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years old, 2009-2011
Payne DC , Boom JA , Staat MA , Edwards KM , Szilagyi PG , Klein EJ , Selvarangan R , Azimi PH , Harrison C , Moffatt M , Johnston SH , Sahni LC , Baker CJ , Rench MA , Donauer S , McNeal M , Chappell J , Weinberg GA , Tasslimi A , Tate JE , Wikswo M , Curns AT , Sulemana I , Mijatovic-Rustempasic S , Esona MD , Bowen MD , Gentsch JR , Parashar UD . Clin Infect Dis 2013 57 (1) 13-20 BACKGROUND: We assessed vaccine effectiveness (VE) for RotaTeq(R) (RV5; 3 doses) and Rotarix(R) (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in geographically and demographically diverse US children. METHODS: We enrolled children <5 years old hospitalized or visiting the ED with AGE symptoms from November 2009 through June 2010 and from November 2010 through June 2011 at 7 medical institutions. Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped. Vaccine receipt among laboratory-confirmed rotavirus cases was compared with AGE children negative for rotavirus (rotavirus-negative AGE controls). Regression models calculated VE estimates for each vaccine, age, ethnicity, predominant genotype, and clinical setting. RESULTS: RV5-specific analyses included 359 rotavirus cases and 1,811 rotavirus-negative AGE controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE controls. RV5 and RV1 were 84% (CI=78%-88%) and 70% (CI=39%-86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 81% (CI=70%-84%) and 86% (CI=74-91%), respectively. RV1 was 78% (CI= 46%-91%) effective against ED rotavirus disease; study power was insufficient to evaluate inpatient RV1 VE. No waning of immunity was evident during the first four years of life for RV5, nor during the first two years of life for RV1. RV5 provided statistically significant genotype-specific protection against each of the four major circulating rotavirus strains (G1P[8], G2P[4], G3P[8], G12P[8]), while RV1 also had a statistically significant VE for the most common genotype, G3P[8]. CONCLUSION: Both RV5 and RV1 significantly protected against medically-attended rotavirus gastroenteritis in this real-world assessment. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure